Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology, Endocrine |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology |
| Healthy: | No |
| Age Range: | 20 - 60 |
| Updated: | 4/28/2018 |
| Start Date: | January 15, 2015 |
| End Date: | November 11, 2019 |
| Contact: | Esha Roy, BS |
| Email: | esharoy@stanford.edu |
| Phone: | 408-313-7538 |
The purpose of this study is to evaluate the relationship between insulin resistance (IR) and
myocardial tissue abnormalities. The study will focus on a patient population, South Asians,
with a high prevalence of IR.
myocardial tissue abnormalities. The study will focus on a patient population, South Asians,
with a high prevalence of IR.
Cardiac fibrosis has been linked to adverse outcomes in non-ischemic cardiomyopathy. Fibrosis
is also detectable in diabetic patients, but does not appear to closely track with insulin
sensitivity. Hence, fibrosis may be an independent risk factor for adverse outcomes in IR and
diabetic patients. As a result, a critical need exists to develop a non-invasive tool to
identify and treat the highest-risk patients. Early detection of cardiac fibrosis and other
CMR- detectable abnormalities in IR patients may help to 'stage' a patient's disease process
and future risk of events, ultimately leading to an adjustment in the aggressiveness of their
medical management and long-term monitoring accordingly. This project is aimed at reducing
the mortality and morbidity associated with insulin resistance and diabetes, and the
investigators believe this project could have a transformative impact on long-term diabetic
care and shed new light upon the biology of diffuse cardiac fibrosis in insulin resistance
and diabetes and its role in shaping the long-term cardiovascular risk for these patients.
is also detectable in diabetic patients, but does not appear to closely track with insulin
sensitivity. Hence, fibrosis may be an independent risk factor for adverse outcomes in IR and
diabetic patients. As a result, a critical need exists to develop a non-invasive tool to
identify and treat the highest-risk patients. Early detection of cardiac fibrosis and other
CMR- detectable abnormalities in IR patients may help to 'stage' a patient's disease process
and future risk of events, ultimately leading to an adjustment in the aggressiveness of their
medical management and long-term monitoring accordingly. This project is aimed at reducing
the mortality and morbidity associated with insulin resistance and diabetes, and the
investigators believe this project could have a transformative impact on long-term diabetic
care and shed new light upon the biology of diffuse cardiac fibrosis in insulin resistance
and diabetes and its role in shaping the long-term cardiovascular risk for these patients.
Inclusion Criteria:
- South Asian
Exclusion Criteria:
- Pregnant women
- Patients with prior diagnoses of diabetes
- Patients on insulin therapy
- Patients with known coronary heart disease or other non-ischemic cardiomyopathies
We found this trial at
1
site
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
Click here to add this to my saved trials
